187 related articles for article (PubMed ID: 12421999)
1. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
Ihn H; Asano Y; Kubo M; Yamane K; Jinnin M; Yazawa N; Fujimoto M; Tamaki K
Rheumatology (Oxford); 2002 Nov; 41(11):1268-72. PubMed ID: 12421999
[TBL] [Abstract][Full Text] [Related]
2. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
Chen F; Shu XM; Wang DX; Xie Y; Wang GC
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
5. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.
Fathi M; Barbasso Helmers S; Lundberg IE
J Intern Med; 2012 Jun; 271(6):589-97. PubMed ID: 21950266
[TBL] [Abstract][Full Text] [Related]
6. [Measurement and clinical significance of serum monocyte chemoattractant protein-1 in patients with polymyosits/dermatomyosits].
Chen F; Shu XM; Wang DX; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):204-8. PubMed ID: 22516988
[TBL] [Abstract][Full Text] [Related]
7. Serum KL-6 in adult patients with polymyositis and dermatomyositis.
Kubo M; Ihn H; Yamane K; Kikuchi K; Yazawa N; Soma Y; Tamaki K
Rheumatology (Oxford); 2000 Jun; 39(6):632-6. PubMed ID: 10888708
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
[TBL] [Abstract][Full Text] [Related]
9. Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis.
Hu C; Wu C; Yang E; Huang H; Xu D; Hou Y; Zhao J; Li M; Xu Z; Zeng X; Wang Q
Clin Rheumatol; 2019 Aug; 38(8):2181-2187. PubMed ID: 30888566
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases.
Shen H; Xia L; Lu J
Cytokine; 2012 Nov; 60(2):334-7. PubMed ID: 22863719
[TBL] [Abstract][Full Text] [Related]
11. HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.
Shu X; Peng Q; Lu X; Wang G
PLoS One; 2016; 11(8):e0161436. PubMed ID: 27537498
[TBL] [Abstract][Full Text] [Related]
12. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis.
Arai S; Kurasawa K; Maezawa R; Owada T; Okada H; Fukuda T
Mod Rheumatol; 2013 Sep; 23(5):872-83. PubMed ID: 22983659
[TBL] [Abstract][Full Text] [Related]
13. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
[TBL] [Abstract][Full Text] [Related]
15. Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis.
Tanaka A; Tsukamoto H; Mitoma H; Kiyohara C; Ueda N; Ayano M; Ohta S; Kimoto Y; Akahoshi M; Arinobu Y; Niiro H; Tada Y; Horiuchi T; Akashi K
Arthritis Res Ther; 2015 Feb; 17(1):27. PubMed ID: 25888887
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum MCP-1 and TGF-β1 in polymyositis/dermatomyositis patients and its significance.
Wu CY; Li L; Zhang LH
Eur J Med Res; 2019 Feb; 24(1):12. PubMed ID: 30764873
[TBL] [Abstract][Full Text] [Related]
17. [The predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis/dermatomyositis].
Wang PZ; Guan JL; Han XH
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jun; 31(6):417-20. PubMed ID: 19031800
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease.
Lou Y; Zheng Y; Fan B; Zhang L; Zhu F; Wang X; Chen Z; Tan X; Wei Q
BMC Pulm Med; 2020 Jul; 20(1):196. PubMed ID: 32680574
[TBL] [Abstract][Full Text] [Related]
20. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.
Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF
Arthritis Rheum; 2011 Nov; 63(11):3439-47. PubMed ID: 21702020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
